Genetic Signature: Metastatic Melanoma Stage Identification

  • Gene expression analyzed in 250 primary and metastatic melanomas procured at the time of surgical resection

  • Approximately 1,000 genes identified to be differentially expressed in the transition from primary to metastatic melanoma

  • A subset of 60 genes for which differential expression is associated with metastatic potential and tumor thickness

FEATURES AND BENEFITS

  • Can aid in the pathology determination of tumor when histology or morphology are inconclusive.

  • Distinguish between new primary tumors or metastasized tumors from a different primary source.

  • Adaptable to gene chip or related diagnostic devices

STAGE OF DEVELOPMENT

The gene expression signature continues to be developed in an effort to minimize the number of genes need for a prognostic test for melanoma aggressiveness

 

PATENT

Utility and PCT

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

06B073